Anixa Biosciences (NasdaqCM:ANIX) FY Conference Transcript

Anixa Biosciences FY Conference Summary Company Overview - Anixa Biosciences is a clinical-stage biotech company focused on oncology, specifically breast and ovarian cancer [2][3] - The company has a robust pipeline including a breast cancer vaccine and a CAR-T technology for ovarian cancer, both currently in phase one clinical trials [2][3] Financial Position - Anixa has a strong balance sheet with no debt and over two years of financial runway, holding approximately $16 million in cash and investments [4][3] - The company has maintained a low cash burn rate, averaging between $5 million and $7 million annually, with only $7 million burned in the last fiscal year [4][5] Partnerships and Collaborations - Anixa collaborates with prestigious institutions like Moffitt Cancer Center and Cleveland Clinic, leveraging their infrastructure to minimize costs [3][5] - The company has received grants, including a Department of Defense grant to support the breast cancer vaccine's phase one clinical trial [7][19] Clinical Trials and Product Pipeline CAR-T Therapy for Ovarian Cancer - The CAR-T therapy is designed to target ovarian cancer cells using a unique target, the follicle-stimulating hormone receptor, which is only expressed in ovarian cells [10][11] - The delivery method is intraperitoneal, allowing for localized treatment and potentially reducing systemic side effects [12][13] - As of the latest update, 12 patients have been dosed with no safety issues reported, and some patients have shown extended survival times [14][15] Breast Cancer Vaccine - The breast cancer vaccine targets alpha-lactalbumin, a protein expressed during lactation, which is also found in various breast cancer cells [17][19] - The phase one trial includes three patient groups: recurrence, prevention, and treatment, with over 70% of patients showing effective immune responses [20][21] - The company plans to transition to phase two trials after compiling data from the current phase one trial [21][22] Market Potential - The breast cancer market is significant, with one in eight women expected to experience breast cancer in the U.S. [24] - Anixa aims to leverage its findings to enter larger markets, including primary prevention and recurrence prevention [24][22] Future Directions - Anixa is exploring additional vaccine targets associated with other cancers, including prostate, lung, and colon cancers, in collaboration with Cleveland Clinic [25] - The company has a strong patent portfolio covering multiple aspects of its vaccine and CAR-T programs, with exclusive worldwide licenses from Cleveland Clinic [26] Conclusion - Anixa Biosciences is well-positioned in the oncology space with a strong financial foundation, promising clinical data, and strategic partnerships, aiming to address significant unmet medical needs in cancer treatment [3][4][5]